XENOTRANSPLANTATION

David Bigam, MD,* Robert Zhong, MD;* Gary Levy, MD;† David Grant, MD*

As transplantation waiting lists lengthen because of the shortage of donor organs, the death rates of patients continue to rise. Xenotransplantation offers the potential to solve the problem of organ shortage by providing an unlimited supply of healthy donor organs. However, there are several barriers to xenotransplantation, including graft rejection, potential xenozoonosis, physiologic incompatibilities and ethical concerns. Experimental xenotransplantation studies continue in several areas, ranging from tissue to whole-organ grafting. Clinical studies continue in the area of tissue xenotransplantation. Trials with extracorporeal xenografts in an acute setting to support fulminant organ failure are likely to begin in the near future. The reintroduction of whole-organ xenotransplantation must be based on sound scientific analysis with broad societal input so as to offer the maximal benefit to transplant recipients and their families.

**WHY DO WE NEED XENOTRANSPLANTATION?**

Transplantation allows patients with organ failure to resume a normal lifestyle. The long-term results of heart, kidney and liver grafting are steadily improving, with 5-year survival rates approaching 70%. Whereas the demand for transplantation has been steadily increasing, organ donation rates have remained relatively constant. Waiting lists continue to increase; currently, almost 3000 Canadians are awaiting an organ transplant. As waiting lists grow, an increasing number of patients will die without ever receiving a transplant.

Many avenues are being pursued to deal with the shortage of donor organs. Although improving health measures to prevent disease may re-
duce organ failure rates, this approach will never be completely effective. Donation rates can be improved, but there will never be enough human organs to meet the demand. Even in a country such as Spain, which has the highest donor rates in the world (38 donors per million people each year compared with 14 donors per million in Canada), there are still not enough donors to fulfill all transplant needs. Artificial organs will undoubtedly play a greater role in the treatment of organ failure, but the technologies will take many years to perfect.

Xenotransplantation offers the potential for an unlimited supply of healthy donor organs. As waiting lists lengthen, many patients decompensate while waiting for a transplant. Xenotransplantation could be performed electively and timed so that both the donor and recipient are in optimal condition before transplantation. Moreover, the donor animal could be matched or manipulated, or both, to facilitate long-term acceptance of the graft without the need for maintenance immunosuppression. Before xenotransplantation can be offered to patients, a number of hurdles must be overcome, including immunologic barriers, disease transmission, physiological differences and ethical concerns.

**PIGS VERSUS PRIMATES**

Although concordant transplants (primate-to-human) might seem to be ideal, there are significant drawbacks to their use, including ethical concerns, transmission of infectious disease, and the cost of breeding and maintaining primates. Currently, pigs are the most promising source of donor organs. Pigs have large litters with a short maturation period, they are easy to breed, and their organ size and physiology are remarkably similar to that of humans. A disadvantage of performing pig-to-human (discordant) transplants is the occurrence of hyperacute rejection, which leads to organ loss within minutes to hours after grafting.

**THE IMMUNOLOGIC REACTION**

The immunologic reaction of the recipient to a xenograft is mediated initially by xenoreactive antibodies, complement and natural killer cells and later primarily by cellular immune responses. These mechanisms result in hyperacute, acute vascular, cellular and chronic graft rejection (Fig. 1).

Hyperacute rejection is a major barrier to discordant xenotransplantation. Humans have natural IgM antibodies (xenoreactive antibodies) to 1,3-galactose, a carbohydrate that is expressed on all nucleated pig cells. After binding of these preformed antibodies, serum complement is activated, resulting in massive thrombosis to vascular endothelium with vessel occlusion and graft failure within minutes to hours of the transplantation. Xenoreactive antibodies can be removed by adsorption columns, but this is only a temporary solution. A more promising approach is to create transgenic pigs expressing selected human genes that modify the immune response. Recently, pigs have been raised that express human complement regulatory genes, thereby preventing activation of complement and ameliorating hyperacute rejection.

The next major hurdle is to prevent acute vascular rejection which leads to graft destruction over a period of days to weeks. Xenoreactive antibodies, macrophages, natural killer cells and complement appear to play important roles in this process. Later (in days to weeks), xenografts may also be damaged by cellular and chronic graft rejection. It is not known whether any of these processes can be reliably prevented by currently available immunosuppressive drugs.

Our centre has evaluated different combinations of antirejection drugs for xenotransplantation in a baboon-to-monkey model and the results have been promising. The combination of
cyclosporine, cyclophosphamide and rapamycin provided long-term survival in concordant kidney xenografts. One monkey with a baboon liver lived for 3 years, despite withdrawal of all immunosuppression 1 year after transplantation.\textsuperscript{11}

Ultimately, the goal of transplantation is to attain a state of tolerance whereby the recipient’s immune system accepts the graft as “self” without the need for maintenance immunosuppression.\textsuperscript{12} The opportunity to genetically manipulate pig donors provides new ways to induce tolerance to xenografts in humans. Donor bone-marrow transplantation, radiation and the production of monoclonal antibodies directed against specific lymphocyte receptors are currently being studied as methods to induce tolerance.\textsuperscript{13–16}

**Xenoislet transplantation**

There have been sporadic attempts at clinical whole-organ xenografting. In the early 1960s, Reemtsma and colleagues\textsuperscript{27} transplanted chimpanzee kidneys into human recipients before dialysis was widely available. Some of these grafts had adequate function.
early, but eventually all of the recipients succumbed to uncontrollable rejection or infection. In 1985, Bailey and associates\(^2\) transplanted a baboon heart into a newborn infant who survived for 3 weeks until the graft was lost to antibody-mediated damage. In 1993, Starzl and colleagues\(^3\) reported a pig liver xenograft as a bridge in an attempt to stabilize her. The liver showed signs of condition until an allograft became available.\(^3\) T he liver showed signs of function but her neurologic status did not improve and she died 34 hours after xenografting.

**ETHICS OF XENOTRANSPLANTATION**

Xenotransplantation raises many important issues related to the application and regulation of new biotechnologies. In Canada, a federal working party, comprising regulatory officials, clinical and laboratory scientists, ethicists, veterinarians and lay people, has been established to determine how, when and if xenotransplantation should proceed. The risk of xenozoonosis poses challenges for obtaining informed consent because there are not only possible hazards for the patient but also for the family and other close contacts. Other ethical issues related to xenografting include animal rights, organ allocation, financing, and the potential psychological responses to receiving and living with tissues from a non-human source.\(^4\)

We believe that prolonged survival should be achieved in a transgenic pig-to-nonhuman primate model before proceeding with clinical whole-organ xenotransplantation. The most likely candidates for the early trials are those patients who are currently excluded from allotransplantation either because they are considered to be at excessive risk or because of a lack of available donors. Potential recipients include the following: highly sensitized patients with renal failure who must wait for years (or indefinitely) until a suitably matched human kidney becomes available; neonates with heart failure who currently face a severe shortage of donors and patients with liver failure secondary to advanced hepatocellular carcinoma; and some patients with viral hepatitis infection. There is some evidence to suggest that xenografts may be preferable to allografts in patients with viral infections that exclusively affect humans.\(^5\)

There will be several economic issues related to the introduction of xenotransplantation into clinical practice. Human organs are generous gifts from donor families, although there are significant costs associated with the organ procurement process. The expenses of xenotransplantation include developing, breeding and maintaining donor animals as well as the costs associated with lifetime surveillance for infectious diseases. If an unlimited supply of donor organs becomes available, many patients who are currently denied transplantation because of risk factors will become candidates for xenotransplantation. This will lead, in turn, to more questions regarding the use of health care resources, minimal listing requirements and the outcomes needed to justify sacrificing donor animals.

**FUTURE DIRECTIONS**

Xenotransplantation offers the potential to save lives and alleviate human suffering. This new technology requires thorough scrutiny at every step, with sound scientific analysis and broad societal input, to ensure that its clinical application proceeds in a timely and safe fashion.

Some of data reported here were supplied by the Canadian Organ Replacement Register, a registry of the Canadian Institute for Health Information. The analysis and interpretation of these data are the responsibility of the author and do not necessarily reflect official policy or interpretation of the Register.

**References**


